MDMA production centers in the Netherlands, which supplies 80 percent of the global total. US emergency department visits involving MDMA rose 72 percent over a recent span. The statistics below cover prevalence, adverse effects, and enforcement patterns.
Key Takeaways
- MDMA acute toxicity LD50 in rats is 19 mg/kg IV
- In 2021, 1.4% of US adults aged 18+ reported past-year MDMA use
- MDMA is Schedule I under US Controlled Substances Act
- MDMA purity in Europe averaged 65% in 2022 tablet form
- MDMA causes 20-50% long-term reduction in serotonin markers in heavy users
- MDMA binds to serotonin transporters with high affinity (Ki=82 nM)
Ecstasy use remains widespread, with patterns varying by age and region despite ongoing risks.
Related reading
01 · Category
Adverse Effects20 stats
01
MDMA acute toxicity LD50 in rats is 19 mg/kg IV
02
Hyperthermia occurs in 70% of MDMA-related ED visits
03
Serotonin syndrome reported in 15-20% of high-dose MDMA overdoses
04
Cardiovascular events like tachycardia in 50% of users acutely
05
Hyponatremia associated with MDMA in 25% of female users due to SIADH
06
Seizures occur in 2-5% of MDMA intoxication cases
07
Acute liver failure linked to MDMA in 1-2 per 100,000 users annually
08
Rhabdomyolysis in 10-15% of severe MDMA hyperthermia cases
09
Acute mortality rate from MDMA is 0.2 per 100,000 users
10
Jaw clenching/bruxism reported by 80% of recreational users
11
Dehydration risk high due to 20-30% increased insensible loss
12
Arrhythmias in 25% of MDMA ED presentations
13
Acute kidney injury in 5% of hyperthermic cases
14
Cerebral edema from hyponatremia fatal in 20% cases
15
Psychosis in 1-3% acute intoxications
16
DIC (disseminated intravascular coagulation) rare but 10% mortality
17
Nausea/vomiting in 30% users onset
18
Myocarditis reported in 0.1% users post-MDMA
19
Teeth grinding leads to 50% needing dental intervention chronic
20
Multiorgan failure in 15% severe overdoses
Interpretation
Adverse Effects Interpretation
While MDMA might promise a night of synthetic bliss, your body essentially endures a chaotic, multi-system revolt where your jaw grinds like it's auditioning for a horror movie, your heart races as if fleeing danger, and your brain chemistry throws a tantrum that can, in rare but starkly real cases, lead to a fatal administrative error in your body's core functions.
02 · Category
Epidemiology20 stats
01
In 2021, 1.4% of US adults aged 18+ reported past-year MDMA use
02
Among US 12th graders in 2022, lifetime MDMA use was 3.2%
03
Global lifetime prevalence of ecstasy use among adults is estimated at 0.4%
04
In Europe, 1.3 million young adults (15-34) reported past-year ecstasy use in 2022
05
Australian past-year ecstasy use among 14-69 year olds was 2.1% in 2022-2023
06
UK lifetime ecstasy use among adults 16-59 was 8.6% in 2021/22
07
In Canada, 1.5% of population aged 15+ reported lifetime MDMA use in 2019
08
US emergency department visits involving MDMA increased 72% from 2011-2019
09
Past-month ecstasy use among US college students was 0.9% in 2021
10
In the Netherlands, 4.2% of adults aged 18-64 reported lifetime ecstasy use in 2022
11
In 2020, 19 million people aged 12+ used ecstasy lifetime in US
12
Past-year use among US young adults (18-25) 2.7% in 2021
13
Lifetime use in US males 1.9% vs females 1.0% aged 12+ 2021
14
European past-30-day use 0.8% young adults 2022
15
Brazilian lifetime prevalence 2.5% urban population 2019
16
South Africa past-year use 0.5% adults 2017
17
New Zealand lifetime use 7.1% adults 2022
18
Russia past-year use 0.3% population 2021
19
Mexico lifetime use 1.2% adults 2016-2017
20
ED visits for MDMA in US: 22,498 in 2011
Interpretation
Epidemiology Interpretation
While these numbers reveal ecstasy's niche appeal, a closer look exposes a troubling public health issue, highlighting its allure, consequences, and regional disparities—from surprisingly high lifetime use in some nations to sharp increases in emergency interventions.
03 · Category
Legal19 stats
01
MDMA is Schedule I under US Controlled Substances Act
02
Global production of MDMA estimated at 200 tons annually
03
DEA seized 12 kg of MDMA in US operations in 2022
04
EU-wide MDMA seizures totaled 23 tons in 2022
05
Average US prison sentence for MDMA trafficking: 5-7 years
06
MDMA possession penalties in UK up to 7 years imprisonment
07
Australian ecstasy arrests numbered 5,200 in 2022
08
Netherlands produces 80% of global MDMA supply
09
US lifetime MDMA arrest rate 0.1% among young adults
10
Schedule I no accepted medical use per DEA 2023
11
EU new psychoactive substances monitoring MDMA analogs 50+
12
US federal MDMA trafficking 5g+ = 40yr max penalty
13
Belgium dismantled 10 MDMA labs 2022 seizing 5 tons
14
Australia class A drug 25yr penalty possession intent supply
15
Canada CDSA Schedule III max 3yr simple possession
16
International treaties 1971 Convention Schedule I
17
FDA breakthrough therapy for PTSD MDMA 2023
18
UK 1.4g possession threshold caution
19
Interpol operations seized 100 tons precursors 2022
Interpretation
Legal Interpretation
The staggering global production of MDMA, juxtaposed with wildly inconsistent international penalties and its emerging therapeutic potential, paints a picture of a world hilariously and tragically unable to agree on whether the substance is a Schedule I scourge or a breakthrough medicine.
More related reading
04 · Category
Market19 stats
01
MDMA purity in Europe averaged 65% in 2022 tablet form
02
Average ecstasy pill weight 300 mg with 150 mg MDMA in EU 2022
03
Street price of MDMA powder $50-100 per gram in US 2023
04
90% of seized ecstasy pills contain MDMA as primary substance
05
Global MDMA market value estimated $5 billion annually
06
PMK-glycid precursor seizures 50 tons in 2022 EU
07
Ecstasy pill logos analyzed: 500 unique in 2022
08
MDMA crystal purity averages 85% in Australian market
09
US tablet MDMA average 120 mg per pill in 2022
10
70% of MDMA trafficked via postal services in EU
11
US MDMA powder $80/g avg retail 2023
12
Pill testing shows 20% contain 2C-B mix 2022 EU
13
Darknet MDMA sales 15% total drug market
14
Average dose per pill 180mg MDMA Netherlands 2022
15
PMK imports China->EU 80% supply chain
16
Australian crystal MDMA $300/g 2023
17
60% tablets <100mg MDMA low dose 2022 US
18
Adulterants caffeine 40%, MDA 15% in seizures
19
Global ecstasy festival seizures 10 tons 2022
Interpretation
Market Interpretation
The ecstasy market now runs with the ruthless efficiency of a multinational corporation, yet still delivers the inconsistent quality of a sketchy backyard mechanic.
05 · Category
Neurotoxicity21 stats
01
MDMA causes 20-50% long-term reduction in serotonin markers in heavy users
02
Memory impairment persists 2 years post-abstinence in ex-users
03
Cortical 5-HT transporter density reduced by 30% after chronic use
04
Hippocampal volume decrease of 4-5% in heavy MDMA users
05
Depression risk increased 2.5-fold in lifetime MDMA users
06
Anxiety disorders 1.8 times higher in ex-MDMA users vs non-users
07
Sleep disturbances in 40% of abstinent users up to 1 year
08
Impulsivity scores elevated 25% in former heavy users
09
Parkinson-like symptoms in 10% of long-term high-dose users
10
Axonal degeneration in serotonin neurons observed in primate models after 5 mg/kg doses
11
Verbal memory deficits with Cohen's d=0.6 in meta-analysis of users
12
SERT density recovery 50% after 24 months abstinence
13
Visual memory impairment d=0.45 in users >50 lifetime doses
14
White matter hyperintensities 2x in heavy users MRI
15
PTSD remission rates 68% with MDMA therapy but neuro changes persist
16
Dopamine transporter reduction 15% long-term
17
Frontal lobe atrophy 3% in chronic users PET
18
Suicide attempt risk 3-fold higher in polysubstance but MDMA contrib
19
Sleep architecture disruption REM rebound absent chronic
20
Decision-making deficits Iowa Gambling Task p<0.01
21
Olfactory memory impaired 20% in ex-users
Interpretation
Neurotoxicity Interpretation
While MDMA may offer a fleeting glimpse of paradise, it seems the bill eventually comes due in the form of a neurological mortgage, with interest paid in memory, mood, and the very architecture of your mind.
06 · Category
Pharmacology20 stats
01
MDMA binds to serotonin transporters with high affinity (Ki=82 nM)
02
Peak plasma concentration of MDMA after 1.5 mg/kg oral dose is 0.2-0.4 μM
03
MDMA half-life averages 8-9 hours in humans
04
MDMA increases dopamine release by 300-500% in nucleus accumbens
05
Serotonin release by MDMA is 10-fold greater than baseline in rat synaptosomes
06
MDMA metabolism primarily via CYP2D6, with 7-10% poor metabolizers showing higher exposure
07
Oral bioavailability of MDMA is approximately 60-75%
08
MDMA induces hyperthermia by inhibiting heat dissipation mechanisms
09
Time to peak effects of MDMA is 1-2 hours post-ingestion
10
MDMA has EC50 for 5-HT release of 156 nM in vitro
11
MDMA inhibits monoamine reuptake via SERT, NET, DAT with Ki 82nM, 1.3uM, 4.5uM
12
MDMA plasma tmax 2.2 hours at 1.5mg/kg dose
13
Elimination half-life 8.4 ± 3.6 hours in healthy volunteers
14
Norepinephrine release increased 400% by MDMA in prefrontal cortex
15
MDMA VMAT2 inhibition leads to 900% cytoplasmic DA increase
16
CYP2D6 ultrarapid metabolizers have 2x faster clearance
17
Rectal bioavailability ~100% vs oral 55%
18
MDMA elevates prolactin 5-fold acutely
19
Duration of empathogenic effects 3-5 hours
20
MDMA Ki for TAAR1 50 nM, contributing to effects
Interpretation
Pharmacology Interpretation
MDMA is a pharmacological sledgehammer that floods your synapses with up to ten times the normal serotonin and nearly quintuples your dopamine, creating a profound but metabolically taxing empathy that peaks in a couple hours and lingers like a demanding guest for half a day.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Julian Richter. (2026, February 13). Ecstasy Statistics. Gitnux. https://gitnux.org/ecstasy-statistics
MLA
Julian Richter. "Ecstasy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ecstasy-statistics.
Chicago
Julian Richter. 2026. "Ecstasy Statistics." Gitnux. https://gitnux.org/ecstasy-statistics.
Sources & references
19 datasets cited across this report · attribution is report-level